DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
DJI46,923.59+0.78%
GDAXI23,564.01+0.50%
GSPC6,696.99+0.98%
HSI25,834.02+1.45%
IXIC22,366.29+1.18%
N22553,751.15-0.13%
AAPL252.29+0.87%
AMZN212.02+2.09%
CL94.12-4.65%
EURUSD1.1518+0.83%
GBPUSD1.3330+0.81%
GC5,015.40-0.91%
GOOG304.17+0.90%
JPM285.98+0.90%
META627.34+2.31%
MSFT399.04+0.88%
NVDA183.18+1.63%
TSLA396.04+1.24%
LIVE
CAN BNN Bloomberg EN

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)

Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) is pleased to announce the commencement of its commercial phased rollout of the Marijuana Breath Test (“MBT”) system. This phase includes the delivery of MBT units to select commercial customers across multiple industries, followed by a planned scale-up in production.

Mar 16, 2026 &03151616202631; 17:15 UTC www.bnnbloomberg.ca Trending 3/5
Read original on www.bnnbloomberg.ca ↗
Positive for markets
Sentiment score: +65/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Cannabix Technologies has launched its commercial rollout of its Marijuana Breath Test (MBT) system, beginning deliveries to select commercial customers across multiple industries with planned production scaling. This represents a significant milestone for the company's cannabis testing technology commercialization.
AI CONFIDENCE
72% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
BLO
BLOStock
Expected to rise
Commercial launch of proprietary MBT technology represents revenue inflection point and validates market demand for cannabis breath testing solutions
BLOZF
BLOZFStock
Expected to rise
OTC listing benefits from positive news regarding product commercialization and multi-industry customer adoption
8CT
8CTStock
Expected to rise
Frankfurt listing exposure to European cannabis testing market expansion and regulatory compliance demand
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Monitor quarterly earnings for customer acquisition numbers and production ramp metrics. Consider accumulating on any pullbacks as commercialization validates the business model; watch for guidance updates on production capacity and customer pipeline expansion.
KEY SIGNALS
Commercial product launch milestone achievedMulti-industry customer acquisition initiatedProduction scaling phase commencingRevenue generation phase beginningRegulatory compliance tool adoption expanding
SECTORS INVOLVED
Cannabis & HempBiotechnologyTesting & DiagnosticsLaw Enforcement Technology
Analysis generated on Mar 16, 2026 at 13:24 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by BNN Bloomberg. Always conduct your own research and consult a qualified financial advisor before making investment decisions.